阿伐曲泊帕治疗儿童和青少年免疫性血小板减少症(AVA-PED-301):一项多中心、随机、双盲、安慰剂对照、3b期研究
AVA-PED-301是一项全球多中心随机双盲安慰剂对照3b期研究,纳入75例持续至少6个月且既往治疗反应不足的儿童和青少年原发免疫性血小板减少症患者,按3:1随机分配至阿伐曲泊帕组(n=54)或安慰剂组(n=21)。阿伐曲泊帕组15例(28%)达到持久血小板应答主要终点,安慰剂组0例(0%),应答率差异28%(95%CI 16-40;p=0.0077);替代主要终点血小板应答率阿伐曲泊帕组44例(81%)vs 安慰剂组0例(0%),差异81%(95%CI 71-92;p<0.0001)。
要点
- 阿伐曲泊帕组持久血小板应答15例(28%),安慰剂组0例(0%),差异28%(95%CI 16-40;p=0.0077)。
- 阿伐曲泊帕组血小板应答44例(81%),安慰剂组0例(0%),差异81%(95%CI 71-92;p<0.0001)。
- 严重不良事件阿伐曲泊帕组5例(9%),安慰剂组1例(5%);未报告死亡、血栓栓塞事件或3级及以上出血事件。
核心结论
- 阿伐曲泊帕是治疗病程至少6个月儿童和青少年ITP的有效口服药物,在儿科人群中安全性令人放心。
- 阿伐曲泊帕可能为儿科ITP提供重要的治疗选择。
研究设计与样本
- AVA-PED-301是一项全球、多中心、随机、双盲、安慰剂对照、平行组、3b期研究。
- 纳入年龄≥1岁至<18岁、确诊原发ITP至少6个月且既往治疗反应不足的儿童和青少年,按3:1随机分配至阿伐曲泊帕组(n=54)或安慰剂组(n=21)。
- 给药方案:≥6岁者口服片剂20 mg每日一次;≥1岁至<6岁者口服混悬液10 mg每日一次,剂量滴定维持血小板计数50-150×10^9/L。
- 核心期为12周双盲治疗期,全分析集包括所有随机分配患者,安全性分析集包括各研究阶段至少接受一剂研究药物的所有患者。
- 主要终点为持久血小板应答:12周治疗期最后8周中至少6次每周血小板计数≥50×10^9/L且未使用补救治疗的患者比例;替代主要终点为血小板应答:12周治疗期内至少连续两次血小板评估≥50×10^9/L且未使用补救治疗的患者比例。
主要发现
- 2021年3月2日至2023年8月2日筛查83例儿童,75例随机分配:阿伐曲泊帕组54例(女性24例[44%];白人48例[89%]),安慰剂组21例(女性12例[57%];白人15例[71%])。
- 达到持久血小板应答主要终点:阿伐曲泊帕组15例(28%)vs 安慰剂组0例(0%),应答率差异28%(95%CI 16-40;p=0.0077)。
- 达到替代主要终点血小板应答:阿伐曲泊帕组44例(81%)vs 安慰剂组0例(0%),应答率差异81%(95%CI 71-92;p<0.0001)。
- 跨治疗组最常见不良事件为瘀点(n=20)、鼻出血(n=16)和头痛(n=14)。
- 严重不良事件:阿伐曲泊帕组5例(9%)vs 安慰剂组1例(5%);未报告死亡、血栓栓塞事件或3级及以上出血事件。
关键数值与推荐
- 持久血小板应答定义:12周治疗期最后8周中至少6次每周血小板计数≥50×10^9/L且未使用补救治疗。
- 血小板应答定义:12周治疗期内至少连续两次血小板评估≥50×10^9/L且未使用补救治疗。
- 剂量滴定目标:维持血小板计数50-150×10^9/L。
临床怎么用
- 阿伐曲泊帕是治疗病程至少6个月儿童和青少年ITP的有效口服药物,在儿科人群中安全性令人放心。
- 阿伐曲泊帕可能为儿科ITP提供重要的治疗选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), taken with food without any specific restrictions, approved for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The aim of this study was to assess the efficacy, safety, tolerability, and pharmacokinetic and pharmacodynamic profile of avatrombopag for children and adolescents with persistent and chronic primary ITP. METHODS: AVA-PED-301 is a global, multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 3b study. Children and adolescents aged ≥1 to <18 years with a confirmed diagnosis of primary ITP for at least 6 months and an insufficient response to a previous treatment were randomly assigned (3:1) to avatrombopag (aged ≥6 years: 20 mg oral tablet once daily; aged ≥1 to <6 years: 10 mg oral suspension once daily) or matching placebo. Doses were titrated to maintain a platelet count of 50-150 × 109 cells per L. The core-phase (12-week double-blind treatment period) full analysis set included all randomly assigned patients; efficacy analysis was performed based on randomised study drug. The safety analysis set included all patients who received at least one dose of study drug in each study phase. The primary endpoint was durable platelet response (proportion of patients with at least six out of eight weekly platelet counts ≥50 × 109 cells per L during the last 8 weeks of the 12-week treatment period in the absence of rescue therapy); the alternative primary endpoint was platelet response (proportion of patients with at least two consecutive platelet assessments ≥50 × 109 cells per L over the 12-week treatment period in the absence of rescue therapy). The trial core phase is complete and was registered with ClinicalTrials.gov (NCT04516967). FINDINGS: Between March 2, 2021, and Aug 2, 2023, 83 children were screened, with 75 randomly assigned to avatrombopag (n=54; 24 [44%] female; 48 [89%] White) or placebo (n=21; 12 [57%] female; 15 [71%] White). 15 (28%) patients in the avatrombopag group met the primary endpoint of durable platelet response versus no (0%) patients in the placebo group (difference in response rate 28% [95% CI 16-40]; p=0·0077); 44 (81%) patients in the avatrombopag group met the alternative primary endpoint of platelet response versus no (0%) patients in the placebo group (difference in response rate 81% [71-92]; p<0·0001). The most common adverse events across treatment groups were petechiae (n=20), epistaxis (n=16), and headache (n=14). Serious adverse events were reported in five (9%) patients in the avatrombopag group and one (5%) patient in the placebo group. No deaths, thromboembolic events, or grade 3 or higher bleeding events were reported. INTERPRETATION: Avatrombopag is an effective oral treatment for children and adolescents with ITP for at least 6 months and has a reassuring safety profile in the paediatric population. Avatrombopag could provide an important treatment option for paediatric ITP. FUNDING: Sobi.
引用
- Grace RF, Leblebisatan G, Aydinok Y, et al. Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study. Lancet Haematol. 2025. PMID: 40418942. doi:10.1016/S2352-3026(25)00107-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。